Atorva+

Pfizer’s Lipitor® (Atorvastatin) was the best-selling pharmaceutical of all time totaling well over $125 billion in sales, prior to becoming generic. Even today, Atorvastatin represents almost half of the estimated $22 billion statin market in the United States.1

 Indication BioScience’s Atorva+ formulation combines an FDA-approved small molecule with Atorvastatin, with an opportunity to create a new improved fixed-dose combination that may have advantages for patients. Indication BioScience also intends to develop additional combination statins including Rosuvastatin, Simvastatin, and Lovastatin.

• 1. JAMA Network Open. 2021;4(11):e2135371. doi:10.1001/jamanetworkopen.2021.35371

Atorva+ has demonstrated in early pre-clinical animal models that it may reverse the  statin-induced side effects

Both active ingredients in Atorva+ are already FDA-approved, allowing for accelerated approval pathway 505b2